Neurobiological Technologies Inc. (NTII)
John Wong of Van Kasper Research initiated coverage with a "buy" and a 12-month price target of $17-19. NTII is a "virtual" biotech company where drug discovery and basic research in neuropharmacology are conducted by a network of scientist shareholders and collaborators before potential products are licensed by the company for clinical development, he